trending Market Intelligence /marketintelligence/en/news-insights/trending/KroeFRVyTDJ2UNLwwDbt9w2 content esgSubNav
In This List

Ra Pharmaceuticals' stockholders approve $2.1B acquisition by Belgium's UCB


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Ra Pharmaceuticals' stockholders approve $2.1B acquisition by Belgium's UCB

Ra Pharmaceuticals Inc.'s stockholders approved the company's acquisition by Brussels-based UCB SA, a deal valued at $2.1 billion.

Cambridge, Mass.-based Ra Pharmaceuticals said the merger agreement was approved at a special meeting of stockholders held Dec. 17.

Under the agreement, UCB is acquiring Ra Pharmaceuticals, an autoimmune disease therapy developer, for $48 per share in cash.

The boards of both companies have already approved the deal.

The acquisition is expected to close by the end of the first quarter of 2020, subject to regulatory approval.

Bank of America Merrill Lynch and Lazard are financial advisers, while Covington & Burling LLP is the legal adviser to UCB.

Centerview Partners is the exclusive financial adviser, while Latham & Watkins LLP is legal adviser to Ra Pharmaceuticals.